The efficacy of cancer treatments has improved constantly in the last decade. However, therapeutic resistance and the lack of curative treatments in metastatic disease, raises the question if conventional anticancer therapies target the right cells. Indeed, these treatments might miss cancer stem cells (CSCs), which might also represent a more chemoresistant and radioresistant subpopulation within cancer. In this view using vaccines in tertiary prevention of cancer, i.e. residual disease treatment, might be particularly effective if vaccine-elicited immune response is directed against CSC oncoantigens (OAs)  proteins required for the neoplastic process  the chance that the tumour will evade the vaccine should be reduced. An important task to devise effective CSC preventive vaccines is therefore the identification of CSC OAs. We used gene-level transcription profiling of B16 mouse melanoma epithelial cell and one mammosphere passage (P1). This analysis allowed the identification of some interesting CSC OAs which are undergoing further studies. SOURCE: Raffaele,A,Calogero (raffaele.calogero@unito.it) - Bioinformatics and Genomics Unit University of Torino

Pluto Bioinformatics

GSE60556: From mouse to humans: detecting preventing vaccination targets associated to melanoma cancer stem cells. Gene-level analysis: B16